Fonar Corp (FONR)
NASDAQ:FONR
Want to see FONR full AI Analyst Report?
Top Page
Fonar
(NASDAQ:FONR)
Select Model
Select Model
Rating:58Neutral
Price Target:
$19.50
▲(38.59% Upside)
Action:Reiterated
Date:05/22/26
The score is driven primarily by pressured operating performance and weaker cash conversion despite a strong, low-leverage balance sheet. Technicals are supportive with price above key moving averages and a positive MACD, but valuation is only average at a ~17.4 P/E, and the going-private deal has a negative legal/disclosure overhang that adds event risk.
Positive Factors
Conservative balance sheet / low leverage
Very low leverage gives Fonar durable financial flexibility: it can fund operations, absorb reimbursement or utilization shocks, invest in service sites or product development, and avoid creditor pressure. A strong equity base reduces solvency risk over the medium term.
Negative Factors
Compressed margins and weak growth
Sustained margin compression and deteriorating top-line growth reduce capacity to reinvest and erode long-term returns. If margins remain below historical norms, the firm may face persistent profit pressure, limiting strategic flexibility and slowing EPS recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low leverage gives Fonar durable financial flexibility: it can fund operations, absorb reimbursement or utilization shocks, invest in service sites or product development, and avoid creditor pressure. A strong equity base reduces solvency risk over the medium term.
Read all positive factors
Fonar Key Performance Indicators (KPIs)
Fonar (FONR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$118.65M
Dividend YieldN/A
Average Volume (3M)29.06K
Price to Earnings (P/E)17.4
Beta (1Y)0.13
Revenue Growth2.25%
EPS Growth-19.05%
CountryUS
Employees520
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.01
Shares Outstanding6,173,008
10 Day Avg. Volume24,606
30 Day Avg. Volume29,056
Financial Highlights & Ratios
PEG Ratio-0.59
Price to Book (P/B)0.55
Price to Sales (P/S)0.91
P/FCF Ratio12.69
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit2.40
Enterprise Value/Ebitda7.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fonar Business Overview & Revenue Model
Company Description
Fonar Corporation (FONR) is a medical technology company focused on the development and manufacturing of advanced magnetic resonance imaging (MRI) systems. The company operates primarily in the healthcare sector, providing innovative imaging solut...
How the Company Makes Money
Fonar makes money primarily through two broad activities: (1) operating diagnostic imaging services and (2) MRI-related equipment and technology. On the services side, the company generates revenue by providing MRI and other diagnostic imaging sca...
Fonar Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
74
Positive
Cash Flow
52
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 105.34M | 104.35M | 102.88M | 98.65M | 97.59M | 89.93M |
| Gross Profit | 42.41M | 42.91M | 45.14M | 45.75M | 47.01M | 43.47M |
| EBITDA | 14.05M | 16.30M | 21.13M | 24.61M | 26.54M | 21.18M |
| Net Income | 6.69M | 8.33M | 10.57M | 9.38M | 12.44M | 10.21M |
Balance Sheet | ||||||
| Total Assets | 219.22M | 216.91M | 214.25M | 200.58M | 199.34M | 189.51M |
| Cash, Cash Equivalents and Short-Term Investments | 53.77M | 56.45M | 56.48M | 51.31M | 48.76M | 44.49M |
| Total Debt | 38.83M | 38.92M | 41.68M | 37.01M | 38.22M | 34.69M |
| Total Liabilities | 54.77M | 56.80M | 57.46M | 49.75M | 53.11M | 54.14M |
| Stockholders Equity | 178.57M | 172.61M | 165.97M | 157.91M | 150.29M | 138.42M |
Cash Flow | ||||||
| Free Cash Flow | 4.51M | 7.45M | 13.27M | 10.13M | 10.67M | 14.27M |
| Operating Cash Flow | 7.59M | 11.26M | 14.09M | 14.47M | 15.30M | 19.09M |
| Investing Cash Flow | -3.58M | -3.80M | -850.74K | -4.34M | -5.18M | -4.82M |
| Financing Cash Flow | -4.61M | -7.47M | -8.18M | -7.57M | -5.86M | -6.61M |
Fonar Technical Analysis
Positive
14.07
Price Trends
18.72
Positive
18.65
Positive
16.89
Positive
Market Momentum
0.04
Positive
62.09
Neutral
82.50
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FONR, the sentiment is Positive. The current price of 14.07 is below the 20-day moving average (MA) of 18.89, below the 50-day MA of 18.72, and below the 200-day MA of 16.89, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 62.09 is Neutral, neither overbought nor oversold. The STOCH value of 82.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FONR.
Fonar Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $369.95M | 34.27 | 10.66% | ― | 23.10% | 22.75% | |
58 Neutral | $118.65M | 17.44 | 3.81% | ― | 2.25% | -19.05% | |
56 Neutral | $67.33M | -6.31 | 3.68% | ― | -0.32% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $423.95M | -13.58 | -17.61% | ― | 3.63% | -93.57% | |
47 Neutral | $128.05M | -2.42 | -47.09% | ― | 15.40% | -25.87% | |
47 Neutral | $517.86M | -7.45 | -20.77% | ― | 3.61% | -568.29% |
* Healthcare Sector Average
FONR
Fonar
18.90
4.63
32.41%
XTNT
Xtant Medical Holdings
0.48
-0.20
-29.62%
VREX
Varex Imaging
10.07
2.24
28.61%
VMD
Viemed Healthcare
9.65
3.05
46.21%
NNOX
Nano-X Imaging
1.84
-3.34
-64.48%
CTKB
Cytek Biosciences
4.01
1.44
56.03%
Fonar Corporate Events
Legal ProceedingsM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Fonar Addresses Merger Disclosure Challenges Ahead of Vote
Negative
May 22, 2026
FONAR Corporation, which develops and markets MRI scanners and related imaging services, is pursuing a going‑private transaction in which an affiliate of CEO and chairman Timothy Damadian will acquire all outstanding shares, leaving FONAR as...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.